EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BRAF (V600E) Mutation in Papillary Thyroid Carcinoma Single Center Experience

Ilir Vela, Igor Dzikovski, Nexhati Jakupi, Goran Kondov, Risto Colancevski, Argjent Muça, Slavica Kostadinova Kunovska, Magdalena Bogdanovska Todorovska, Sinisa Stojanoski

Kosova Journal of Surgery · 15.06.2024 · 8 (1) · 42-46

DOI: 10.59928/q8ef5y79 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kosova Journal of Surgery, online erschienen am 15.06.2024. Verfasst von Ilir Vela und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BRAF has an important role in cellular proliferation, differentiation, and programmed cell death. The BRAF(V600E) gene mutation has recently been found to be present in various types of cancers. Studies on the BRAF(V600E) mutation in thyroid cancer are intensively examined in various countries, showing that the presence of the BRAF(V600E) mutation varies and ranges from 28% to 86% in papillary thyroid carcino ma. Papillary thyroid carcinoma is the most common type of endocrine malignancy, accounting for 85–90% of all thyroid cancers. However, there is a lack of suffi cient studies in the Republic of Macedonia regarding the expression of the BRAF(V600E) mutation in papillary thyroid carcinoma. The aim of the study was to analyze the expression of the gene mutation BRAF(V600E) in papillary thyroid carcinoma and the correlation between expression and clinicopathological characteristics. The study population consisted of 35 patients. The cobas4800 BRAFV600E Mutation IVD test was used for detection of mutations in the BRAF gene, which was performed on the Cobas Z 480 IVD Real-Time PCR instrument (Roche Diagnostic). The test kit included appropriate controls (wild type and mutant). Patients with lymph node metastases had a higher risk of BRAF V600E gene mutation compared to patients without lymph node metastasis of the tumor. Greater patient age, invasion of the capsule, multifocality, and male gender were factors associated with increased expression of the BRAF V600E gene mutation.

Zitieren

APA

Vela, I., Dzikovski, I., Jakupi, N., Kondov, G., Colancevski, R., Muça, A., Kunovska, S. K., Todorovska, M. B., & Stojanoski, S. (2024). BRAF (V600E) Mutation in Papillary Thyroid Carcinoma Single Center Experience. Kosova Journal of Surgery, 8(1), 42-46. https://doi.org/10.59928/q8ef5y79

Vancouver

Vela I, Dzikovski I, Jakupi N, Kondov G, Colancevski R, Muça A, et al. BRAF (V600E) Mutation in Papillary Thyroid Carcinoma Single Center Experience. Kosova Journal of Surgery. 2024;8(1):42-46. doi:10.59928/q8ef5y79

BibTeX
@article{Vela2024,
  author = {Vela, Ilir and Dzikovski, Igor and Jakupi, Nexhati and Kondov, Goran and Colancevski, Risto and Muça, Argjent and Kunovska, Slavica Kostadinova and Todorovska, Magdalena Bogdanovska and Stojanoski, Sinisa},
  title = {BRAF (V600E) Mutation in Papillary Thyroid Carcinoma Single Center Experience},
  journal = {Kosova Journal of Surgery},
  year = {2024},
  volume = {8},
  number = {1},
  pages = {42--46},
  doi = {10.59928/q8ef5y79}
}
Kostenlos starten →